GH1 and neoplasm: This apparent discrepancy could be because of the specific E‐cadherin antibody used.36 We observed a similar proportion of GH‐producing tumours displaying none or very low membranous E‐cadherin immunoreactivity compared to some studies17, 18 but a higher proportion compared to other studies.19, 23, 37 These discordant results could be related, at least partly, to differences in patients included in the studies.